How Indian Health IT Firms Are Winning US Digital Health Work

I keep hearing the same sentence in buying meetings: “We need a partner who already knows US healthcare.” That used to be a soft preference. In 2026, it is the filter.

The Indian services firms that are landing more US digital health contracts are not selling generic delivery anymore. They are selling credibility artifacts. HIPAA centers of excellence. Epic certification programs. AI-first delivery playbooks. Security attestations. Integration benches that can speak HL7v2 on Monday, FHIR R4 on Tuesday, and X12 when revenue cycle gets dragged into the room.

That sounds like marketing, and some of it is. I have sat through enough vendor pitches to know the difference between a real operating model and a slide with a compliance badge pasted on it. The difference shows up in the first two weeks: how they handle environment access, who is allowed to see PHI, whether they can map a broken interface without asking the client to rewrite the whole workflow around them.

We have seen this pattern inside AST’s own delivery work too. When we tie an engineering pod to a real care workflow, the conversation changes fast. The client stops asking whether the team has “worked in healthcare” and starts asking whether the team can survive the actual friction: sandbox delays, interface control documents that do not match reality, release windows that explode when a downstream dependency changes.

That is where the Indian firms are sharpening their pitch. They know the old offshore story is weak in healthcare because healthcare punishes handoffs. So they are moving closer to the work with US-facing solution architects, vertical accelerators, and delivery models that look more like integrated pods than classic staff augmentation.

Why the old offshore playbook stopped working

Ten years ago, a lot of buyers judged firms on labor arbitrage and scale. That model still exists, but it is not enough for digital health. The reason is simple: healthcare software is not a clean code factory. It is a system of systems, and every system has a patient safety or reimbursement consequence attached to it.

So when a firm says it can build a portal, an integration layer, an auth workflow, and an analytics pipeline, I ask one question: how do they prevent the very normal failures that happen in healthcare delivery?

• Who owns PHI handling in non-production environments?
• How are Epic, HL7v2, and FHIR mappings validated before UAT?
• What happens when a payer response breaks a prior auth workflow at 5 p.m. on a Friday?
• Can the team explain the difference between a technical success and a clinic-safe launch?

The firms winning contracts in 2026 answer those questions directly. The ones still selling generic nearshore/offshore capacity stumble. They talk about velocity, but they do not talk enough about failure modes.

How Infosys, Wipro, and HCL are packaging credibility

Let’s be clear: the big Indian firms are not competing the same way. But they are all converging on a similar answer to the US market’s distrust of generic outsourcing: make healthcare delivery feel pre-approved.

Here is what that looks like in practice.

The AI-first message is especially interesting because it is both powerful and easy to oversell. In healthcare engineering, AI helps in narrow places: test case generation, code summarization, documentation cleanup, interface log triage. It does not magically understand why a prior auth workflow depends on a payer-specific status code or why a clinical message must be routed to a specific inbox instead of a generic queue.

I have watched teams assume that an AI-assisted delivery model can compensate for weak healthcare domain depth. It cannot. In fact, it can make the gap more obvious because it speeds up the wrong decisions. The best firms use AI to remove repetitive work, then keep humans in the loop where workflow, compliance, and interoperability meet.

AST’s view from the delivery side

At AST, we work in the part of the market where the buyer does not want a theory deck. They want a team that can connect systems without breaking the clinic day. That means our conversations start with the workflow, not the framework.

That perspective matters because the Indian firms are now competing on the same terrain. They are learning that US buyers will pay for a partner who understands the operational mess: legacy HL7v2 feeds, half-documented interface ownership, FHIR endpoints that exist in principle but not in practice, and compliance checkpoints that arrive late only if the team is inexperienced.

The best engagements we’ve seen inside AST’s EHR integration work start with a boring question: what breaks if this system goes live exactly as designed? That question exposes whether the vendor has healthcare reflexes. Great firms answer with blast-radius thinking. Weak firms answer with optimism.

That is also why the services firms investing in Epic certification pipelines matter. Certifications do not guarantee delivery quality, but they lower the odds that a team will learn the system on the client’s clock. The same is true for compliance-trained delivery pods. If the team already knows how to operate inside PHI constraints, the buyer gets to spend their time on product decisions instead of policing basic process.

What actually wins US digital health contracts in 2026

I do not think the market is rewarding the biggest firm automatically. I think it is rewarding the firm that makes risk feel controllable. That is a different game.

1. Show healthcare operating muscle, not just engineering headcount Put the delivery model on the table. Who has done HIPAA reviews? Who owns interface governance? Who signs off on PHI handling? Buyers want to know the machine, not just the resumes.
2. Prove you can integrate with the systems that actually run care Epic, Cerner/Oracle Health, athenahealth, PointClickCare, HL7v2, FHIR R4, and X12 are not acronyms to sprinkle into a deck. They are the terrain. If the partner cannot explain the coupling points, they are guessing.
3. Use AI where it reduces toil, not where it hides ignorance AI should accelerate code review, test creation, documentation, and support triage. It should not be the excuse for skipping domain discovery or compliance design.
4. Build proof around governed delivery Buyers look for secure dev environments, change control, logging, and auditability. This is where HIPAA and SOC 2 talk becomes real. If the vendor cannot show the controls, the rest of the pitch is noise.
5. Shorten trust-building by bringing healthcare people into the first conversation Not salespeople with a healthcare slide. Actual delivery leaders who can explain how a release lands in a live care setting.

That last step is more important than vendors admit. In our own work, I have seen deals accelerate the minute the client realizes they are speaking to people who have actually shipped in healthcare. The confidence shift is immediate because the buyer stops having to translate basic terms like downtime, auth, interface retries, or clinic workflow exceptions.

The friction nobody likes to say out loud

Here is the counterintuitive part: some of the biggest Indian firms are getting better at selling healthcare faster than some healthcare-native shops are getting better at scaling themselves.

That should make everyone uncomfortable, including me. We like to assume healthcare-native automatically means safer. It does not. Plenty of healthcare-only teams are trapped in slow, bespoke delivery habits, while the large services firms are building reusable healthcare assets, tighter governance, and more disciplined onboarding.

But there is a catch. Reusability only helps if it does not flatten the workflow. I have seen modular delivery become a liability when teams start forcing the client into the template. In healthcare, the template has to bend to the clinic, not the other way around. That is the mistake I still see most often in outsourced digital health work.

If you are buying digital health services in 2026, the right question is not “Who is cheapest?” It is “Who will still be useful when the integration gets ugly?” That is the real test, and it separates a presentation from an operating partner.

At AST, we keep coming back to the same lesson: healthcare buyers do not need more promises. They need fewer surprises. The firms that understand that are the ones winning.